Publications by authors named "N Osman"
Three-year course of clinical high-risk symptoms for psychosis in the community: a latent class analysis.
Epidemiol Psychiatr Sci
January 2025
Aims: Clinical high-risk for psychosis (CHR-P) states exhibit diverse clinical presentations, prompting a shift towards broader outcome assessments beyond psychosis manifestation. To elucidate more uniform clinical profiles and their trajectories, we investigated CHR-P profiles in a community sample.
Methods: Participants ( = 829; baseline age: 16-40 years) comprised individuals from a Swiss community sample who were followed up over roughly 3 years.
Background: Childhood adversities and traumata (CAT) increase the risk for various mental disorders, including the clinical high-risk of psychosis (CHR-P) state and its main comorbidities, i.e., depression, and social phobia.
View Article and Find Full Text PDFBackground: In endemic COVID-19, immunocompromised children are vulnerable until vaccinated but the optimal primary vaccination regime and need for booster doses remains uncertain.
Methods: We recruited 19 immunocompromised children (post-solid organ transplantation, have autoimmune disease or were on current or recent chemotherapy for acute lymphoblastic leukemia), and followed them from the start of primary vaccination with BNT162b2 mRNA SARS-CoV-2 until 1-year post-vaccination. We investigated the quality of vaccine immunogenicity, and longevity of hybrid immunity, in comparison to healthy children.
Background: The neglected tropical disease leishmaniasis has significant adverse effects from current treatments and limited therapeutic options are currently available.
Objective: The aim of this study was to develop a surface-modified nano-liposomal drug delivery system, anchored with chondroitin sulfate (CS), to effectively transport Amphotericin B (AmB) to macrophages.
Methods: Conventional liposome formulations (CL-F) and CS-coated surface-modified liposome formulations (CS-SML-F) were formulated by the thin film hydration method and characterized for particle size, polydispersity index (PDI), zeta potential, and entrapment efficiency with long-term stability.
Article Synopsis
- Intravenous polyvalent immunoglobulins (IVIG) are vital for patients with primary immunodeficiency disorders (PIDs) but access can be limited in lower middle-income countries; the WHO suggests local production using new technologies.
- A clinical study compared the safety and effectiveness of mini-pool IVIG (MP-IVIG) to standard IVIG (STD-IVIG) in 21 pediatric PID patients, finding that both treatments reduced severe bacterial infections and hospitalizations.
- Results showed that MP-IVIG did not present safety issues and was as effective as STD-IVIG, although findings should be interpreted cautiously due to the small sample size.